OrbiMed

Avitide, Inc. specializes in the discovery, manufacture, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, the company focuses on developing customized affinity purification products that improve the efficiency and effectiveness of bioprocessing. Avitide's technology enhances the purification of therapeutic proteins, including enzymes, antibodies, gene therapies, and vaccines, by employing rapid development of chromatography resins through chemical synthesis. This advanced platform enables clients to accelerate bioprocess development timelines, mitigate program risks, and achieve predictable commercial scalability while lowering manufacturing costs in both batch and continuous operations.

Avitide, Inc. specializes in the discovery, manufacture, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, the company focuses on developing customized affinity purification products that improve the efficiency and effectiveness of bioprocessing. Avitide's technology enhances the purification of therapeutic proteins, including enzymes, antibodies, gene therapies, and vaccines, by employing rapid development of chromatography resins through chemical synthesis. This advanced platform enables clients to accelerate bioprocess development timelines, mitigate program risks, and achieve predictable commercial scalability while lowering manufacturing costs in both batch and continuous operations.

Avitide, Inc. specializes in the discovery, manufacture, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, the company focuses on developing customized affinity purification products that improve the efficiency and effectiveness of bioprocessing. Avitide's technology enhances the purification of therapeutic proteins, including enzymes, antibodies, gene therapies, and vaccines, by employing rapid development of chromatography resins through chemical synthesis. This advanced platform enables clients to accelerate bioprocess development timelines, mitigate program risks, and achieve predictable commercial scalability while lowering manufacturing costs in both batch and continuous operations.

Adimab LLC is a biotechnology company specializing in the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes a yeast-based platform to create therapeutic antibodies, including IgG and CD3-based bispecific antibodies. The company is recognized for its ability to deliver diverse and high-quality antibody panels that adhere to stringent standards for affinity, epitope coverage, and species cross-reactivity. This capability allows Adimab to support its partners in rapidly expanding their biologics pipelines through various technology access arrangements. The company's work primarily targets the treatment of cancer, autoimmune disorders, and infectious diseases.

Adimab LLC is a biotechnology company specializing in the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes a yeast-based platform to create therapeutic antibodies, including IgG and CD3-based bispecific antibodies. The company is recognized for its ability to deliver diverse and high-quality antibody panels that adhere to stringent standards for affinity, epitope coverage, and species cross-reactivity. This capability allows Adimab to support its partners in rapidly expanding their biologics pipelines through various technology access arrangements. The company's work primarily targets the treatment of cancer, autoimmune disorders, and infectious diseases.